TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2109643
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg (intravenous injection)
Study: 7350046
Drug: Mitochondrial antibody
Normalized name: Mitochondrial antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitochondrial antibody titer
Study: 31839281
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg per day, oral)
Study: 21550429
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol treatment (0.05mg/day)
Study: 18461844
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) orientation
Study: 18461844
Drug: Prior supportive
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior supportive therapy training
Study: 16188948
Drug: SSc patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSc patients with serum anti-Scl70 antibodies
Study: 12686335
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/day plus fenofibrate 200 mg/day
Study: 11052841
Drug: Nadroparin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (2 ml of 2500 anti-Xa-units/ml with a microporous catheter)
Study: 11052841
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no local drug delivery)
Study: 7606629
Drug: Caffeine (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (three times daily for 6 days)
Study: 28762606
Drug: D-dimer-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer-guided warfarin therapy (low intensity adjusted to standard intensity based on D-dimer levels)
Study: 28762606
Drug: D-dimer-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer-guided warfarin therapy
Study: 28762606
Drug: Standard intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensity warfarin therapy (INR 2.5-3.5)
Study: 28762606
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity warfarin therapy (INR 1.8-2.6)
Study: 11094003
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine at 10 mL/h via a disposable infusion pump
Study: 11094003
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline at 10 mL/h via a disposable infusion pump
Study: 8054250
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg rac-ibuprofen
Study: 8054250
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg rac-ibuprofen
Study: 3047100
Drug: Triazolam 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.5 mg nightly for 5 weeks
Study: 31994303
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg ferrous sulfate twice a day (total elemental iron dose: 160 mg / day)
Study: 31994303
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg ferrous sulfate once a day (total elemental iron dose: 80 mg / day)
Study: 31994303
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg ferrous sulfate every other day (total elemental iron dose: 80 mg / every other day)
Study: 25922062
Drug: Mito-FLAG with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mito-FLAG with Ara-C as bolus (1000 mg/m(2) over 1 h, every 12 h, days 1-5)
Study: 25922062
Drug: Mito-FLAG with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mito-FLAG with Ara-C as continuous infusion (150 mg/m(2) over 24 h, days 1-5)
Study: 25922062
Drug: Mito-FLAG with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mito-FLAG with Ara-C as continuous infusion
Study: 23827771
Drug: Betamethasone +
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone + Essex® cream
Study: 23827771
Drug: Essex® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essex® cream
Study: 23827771
Drug: Canoderm® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canoderm® cream
Study: 21062464
Drug: NRT oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype)
Study: 21062464
Drug: NRT oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)
Study: 18476606
Drug: BCG-PSN 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-PSN 1.0 mg twice a week for two months
Study: 18476606
Drug: Intranasal azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal azelastine twice a day as needed
Study: 14658986
Drug: Long-term pharmacotherapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term pharmacotherapy
Study: 14658986
Drug: Psychotherapy (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (alone or combined with medication)
Study: 9534995
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate vaccines
Study: 6697786
Drug: Inhaled glycopyrrolate
Normalized name: glycopyrrolate Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glycopyrrolate (1.3 mg)
Study: 6697786
Drug: Atropine (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (2.6 mg)
Study: 31525242
Drug: Mothers whose
Normalized name: Allium fistulosum whoe extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothers whose household monthly income was more than $100
Study: 29409494
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine Zengru Gao
Study: 27045034
Drug: Fenretinide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (oral retinoid) for 2 years
Study: 27045034
Drug: Baseline VEGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline VEGF levels in the top quintile (≥350 pg/mL)
Study: 24578135
Drug: Neutralization of
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralization of Dkk1 using a monoclonal antibody after renal injury
Study: 24578135
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Dkk1 antibody and phosphate binder therapy
Study: 12208481
Drug: Pravastatin (CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (CC genotype)
Study: 10206198
Drug: Expectant management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant management (no further treatment)
Study: 2217010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiopentone and etomidate (5:1 ratio)
Study: 2217010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiopentone and etomidate (13:1 ratio)
Study: 2217010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiopentone and etomidate (25:1 ratio)
Study: 6994960
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what treatment was used)
Study: 27801706
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy + Calcium + Vitamin D (HT + Ca/D)
Study: 25874723
Drug: HIV-DNA vaccine
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-DNA vaccine containing plasmids expressing HIV-1 gp160 subtypes A, B, C, Rev B, Gag A, B and RTmut B, followed by recombinant HIV-MVA boost expressing CRF01_AE HIV-1 Env subtype E and Gag-Pol subtype A.
Study: 16418018
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg 1 hour before surgery, then 200 mg every 12 hours for the first 5 days
Study: 9211578
Drug: Thiamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (5 g)
Study: 9211578
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g lactose)
Study: 8433254
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl 50 mg/ml
Study: 8433254
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl 10 mg/ml
Study: 28892591
Drug: Etanercept 10
Normalized name: Etanercept 10 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 10 mg once-weekly
Study: 28892591
Drug: Etanercept 10
Normalized name: Etanercept 10 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 10 mg twice-weekly
Study: 28892591
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg every 2 weeks
Study: 28892591
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once-weekly
Study: 27660305
Drug: Lung ultrasound-guided
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound-guided ultrafiltration prescription policy
Study: 25068411
Drug: Lidocaine 3
Normalized name: Lidocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 3 mg/kg plus ketamine 50 mg
Study: 20737642
Drug: Fenofibrate immediate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate immediate release (IR) tablet formulations
Study: 20737642
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing sodium lauryl sulfate (SLS)
Study: 1331992
Drug: lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lomefloxacin 400 mg
Study: 1331992
Drug: ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 750 mg
Study: 28674856
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiglaucoma medications)
Study: 27401892
Drug: onartuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: onartuzumab (10 mg/kg) plus mFOLFOX6
Study: 27401892
Drug: onartuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: onartuzumab (10 mg/kg) plus mFOLFOX6 in MET-positive population
Study: 18242415
Drug: Nutritious supplement
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritious supplement (atole)
Study: 18242415
Drug: Less nutritious
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less nutritious supplement (fresco)
Study: 16193892
Drug: Avonex® (interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avonex® (interferon beta-la) 30 μg, intramuscular, once weekly
Study: 10628579
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (tricyclic antidepressants, antiserotonin antidepressants, selective serotonin reuptake inhibitors, or multiple agents)
Study: 2025805
Drug: Topical Xylocaine
Normalized name: Xylocaine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Xylocaine
Study: 6277018
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg given twice daily for 4 weeks
Study: 6277018
Drug: Ranitidine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine for a further 4-week period after initial treatment
Study: 31936725
Drug: Once-weekly sprint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly sprint interval training (SIT)
Study: 31936725
Drug: Twice-weekly sprint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly sprint interval training (SIT)
Study: 15355358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hydroquinone cream and sunscreens)
Study: 7865920
Drug: Individual, direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual, direct speech and language therapy (third group)
Study: 30958045
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg octacosanol intake
Study: 24890674
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate cream or ointment administered once or twice daily
Study: 20940336
Drug: PI-2301 (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-2301 (0.035 to 60 mg subcutaneous injection)
Study: 20940336
Drug: PI-2301 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-2301 (10, 30, and 60 mg cohorts)
Study: 20940336
Drug: PI-2301 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-2301 (1, 3, or 10 mg)
Study: 20940336
Drug: PI-2301 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-2301 (30 or 60 mg)
Study: 15236997
Drug: Early-hCG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-hCG group (10000 IU hCG administered as soon as at least three follicles were >=17 mm on ultrasound)
Study: 15236997
Drug: Late-hCG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-hCG group (10000 IU hCG administered 2 days after the criterion was met)
Study: 11585881
Drug: L&W with
Approvals — FDA: no, EMA: no, PMDA: no
Description: L&W with tPA (4 mg)
Study: 11585881
Drug: L&W with
Approvals — FDA: no, EMA: no, PMDA: no
Description: L&W with urokinase (UK) (250,000 U)
Study: 24320206
Drug: Bidirectional knotless
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidirectional knotless barbed suture (Quill™‐0; Angiotech Pharmaceuticals, Inc.)
Study: 22078155
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (50 mg/mL, 5 mg per 0.1 mL, administered once in 1 nostril)
Study: 22078155
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (2.5 mg, infused over 10 seconds)
Study: 18653268
Drug: ARB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB treatment (valsartan, candesartan, losartan)
Study: 7495191
Drug: Vigabatrin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin as add-on therapy
Study: 1369725
Drug: Naftidrofuryl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (2 x 316.5 mg tablets daily with meals) for 6 months
Study: 1369725
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets daily during washout and treatment)
Study: 30709958
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) monotherapy for 3 months
Study: 30709958
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline levels of tumor necrosis factor receptor I (TNF-RI)
Study: 30709958
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline levels of vascular cell adhesion molecule 1 (VCAM-1)
Study: 23645886
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 20 μg/day
Study: 23645886
Drug: Ex-BID (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex-BID (twice-daily exenatide injections) 5 → 10 μg
Study: 23645886
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 60 μg/day
Study: 23645886
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 80 μg/day
Study: 23645886
Drug: All ITCA
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All ITCA 650 groups except 20 → 20 μg/day
Study: 19678443
Drug: Duraphat (Colgate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraphat (Colgate Oral Pharmaceuticals, Inc)
Study: 15284257
Drug: FEC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 100 (epirubicin 100 mg/m²)
Study: 15284257
Drug: FEC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 50 (epirubicin 50 mg/m²)
Study: 11528252
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) >500 million units total dose
Study: 11528252
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) <=500 million units total dose
Study: 11528252
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) >500 million units total dose in patients with histology F2 or F3
Study: 19422759
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (olanzapine, quetiapine, risperidone) combined with SSRI and cognitive-behavioral therapy (CBT) for 1 year
Study: 19422759
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) plus cognitive-behavioral therapy (CBT) for 1 year
Study: 15385013
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg x kg(‐1) bolus followed by 100 microg x kg(‐1) x min(‐1) infusion)
Study: 15385013
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg x kg(‐1) bolus after 0.5 mg x kg(‐1) bolus of ketamine followed by 75 microg x kg(‐1) x min(‐1) infusion)
Study: 11527684
Drug: Neoadjuvant regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy (etoposide, ifosfamide, doxorubicin)
Study: 11527684
Drug: Neoadjuvant regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy
Study: 1977089
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg nocte
Study: 28501869
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) progesterone 50 mg in oil, single daily injection
Study: 28501869
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone 200 mg micronized, 3 times daily
Study: 20393026
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy (CRT) with 4 weeks' PSK administration
Study: 18468761
Drug: Palatal mucoadhesive
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palatal mucoadhesive tablet containing herbal formulation
Study: 18468761
Drug: Herbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formulation ingredients (sage, Echinacea, Lavender, Mastic gum)
Study: 12917867
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy (n=34)
Study: 10343785
Drug: lorazepam (0.038
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (0.038 mg kg‐1)
Study: 1746465
Drug: Intracoronary diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary diltiazem (0.5 mg)
Study: 1746465
Drug: Intracoronary diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary diltiazem (0.5 mg) with placebo pretreatment
Study: 1746465
Drug: Intracoronary diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary diltiazem (0.5 mg) with isosorbide dinitrate pretreatment
Study: 7102536
Drug: Propranolol (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10, 20, and 40 mg four times a day)
Study: 7102536
Drug: Pindolol (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (2.5, 5, and 10 mg four times a day)
Study: 30143387
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride nasal gel at 6.0mg/g
Study: 30143387
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride nasal gel at 4.5mg/g
Study: 30143387
Drug: Both concentrations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both concentrations (6.0mg/g and 4.5mg/g)
Study: 25022116
Drug: Acupuncture (warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (warming needling manipulation at key acupoints Hegu (LI 4) and Taichong (LR 3), once a day for 10 treatments, 2 sessions total)
Study: 25022116
Drug: Medication (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (2.5 mg diazepam tablets, three times a day for 23 days)
Study: 20026538
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of antibiotic prophylaxis
Study: 14707430
Drug: Olive oil-based
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil-based emulsion (0.16 g/kg/h for 3 hours)
Study: 14707430
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil + medium chain fatty acid (MCT) emulsion (0.16 g/kg/h for 3 hours)
Study: 11367869
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (intramuscular methotrexate 12.5 mg/week, oral sulphasalazine 0.5 g b.i.d., indometacin 100 mg suppository at bed-time)
Study: 11367869
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus antioxidant combination